MI-LINEAGE-LOGISTICS
2.11.2021 08:02:13 CET | Business Wire | Pressemeddelelse
Lineage Logistics, LLC (”Lineage” eller ”selskabet”), en førende global udbyder af temperaturstyret industriel REIT og logistikløsninger, meddelte i dag, at de har afsluttet opkøbet af køleopbevaringsafdelingen i Claus Sørensen Gruppen, en anerkendt operatør inden for køleopbevaring i Danmark.
Købet blev først annonceret den 15. juni 2021.
Udvidelsen i Danmark er en afgørende del af Lineages vækstplaner i Norden. Opkøbet giver Lineages globale rækkevidde en vigtig forbindelse til Danmark, som er ved at udvikle sig til et førende europæisk midtpunkt inden for den globale køleopbevaringsforsyningskæde, med luftfragt og søfartsinfrastruktur i verdensklasse.
Virksomhedens nuværende tilstedeværelse i Danmark forstærkes igennem Lineages opkøb af Claus Sørensen og tilføjer betydelige volumener på strategiske lokationer nær danske havne og centre for fødevareproduktion.
”Claus Sørensens relationer og tilgang til forretning vil sætte skub i vores vækstplaner i Norden”, siger Harld Peters, Senior Vice President for Europa hos Lineage. ”Vi ser frem til at arbejde sammen med dem for at betjene vores kunder i hele Europa”.
Claus Sørensen, som har hovedkvarter i Esbjerg, har en kapacitet på næsten en million kubikmeter og 200.000 pallepositioner fordelt på ni lagre og mere end 250 teammedlemmer. Med opkøbet og færdiggørelsen af igangværende byggeri i regionen, vil Lineages samlede fodaftryk i Danmark omfatte 17 lokationer og næsten 300.000 pallepositioner.
Claus Sørensen leverer køleopbevaring til kød og fjerkræ, brød, is, færdigretter, frugt og grønt og mejeriprodukter. Ud over opbevaring leverer virksomheden blæsefrysning, kvalitetskontrol, ordresammensætning og pakning, isproduktion, told og distribution til detailhandel og catering. Claus Sørensen kan fryse 1.800 tons produkter om dagen. Claus Sørensen er som et vigtigt led i den danske fødevare- og drikkevareforsyningskæde gået sammen med sine kunder for at forbedre deres forsyningskædeoperationer, opnå maksimal energiudnyttelse og beskytte miljøet.
”Lineage er stærkt engagerede i både innovation og service, hvilket passer perfekt til vores mangeårige forpligtelse til at være vores kunders foretrukne partner”, siger Jesper Toft Mathiasen, CEO hos Claus Sørensen. ”Vi glæder os til at blive en del af en virksomhed, der deler vores værdier, og til at slå os sammen med Lineages team i regionen for at transformere vores kunders forsyningskæde og hjælpe dem med at få deres forretninger til at vokse”.
Lineage Logistics kom ind på det nordiske marked i 2020. Siden da har virksomheden opkøbt Lundsøe Køl & Frys A/S med kølelagerfaciliteter i Nordjylland og Aarhus, Super Frost Sjælland ApS og Coldstar ApS, udover opkøbet af Claus Sørensen.
Om Lineage Logistics: Lineage Logistics er en førende udbyder af temperaturstyret industriel REIT og logistikløsninger. Firmaet har et globalt netværk på over 400 strategisk placerede faciliteter med en samlet kapacitet på over 60 millioner kubikmeter, der spænder over 19 lande fra Nordamerika, Europa og Asien-Stillehavsområdet. Lineages ekspertise indenfor brugsklare løsninger, deres uovertrufne netværk af fast ejendom og udvikling af innovativ teknologi er med til at øge distributionseffektiviteten, fremme bæredygtighed, minimere spild i forsyningskæden og, vigtigst af alt, som visionær partner med Feeding America, være med til at brødføde verden. Som en anerkendelse af firmaets initiativer inden for innovation og bæredygtighed opnåede Lineage at blive nr. 17 på CNBC Disruptor 50-listen i 2021, nr. 1 som bedste datavidenskabsvirksomhed og samlet nr. 23 på Fast Companys liste over verdens mest innovative virksomheder i 2019, udover at være med på Fortunes Change The World-liste i 2020. (www.lineagelogistics.com )
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20211102005519/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
